Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Mar 4, 2022
Date Accepted: Jun 6, 2022
Date Submitted to PubMed: Aug 26, 2023

The final, peer-reviewed published version of this preprint can be found here:

Pharmaceutical Payments to Authors of Dermatology Guidelines After Publication

Sivesind TE, Szeto MD, Anderson J, Maghfour J, Matheny M, Le QNM, Kamara M, Dellavalle R

Pharmaceutical Payments to Authors of Dermatology Guidelines After Publication

JMIR Dermatol 2022;5(2):e37749

DOI: 10.2196/37749

PMID: 37632871

PMCID: 10334891

Pharmaceutical Payments to Authors of Dermatology Guidelines After Publication

  • Torunn Elise Sivesind; 
  • Mindy D. Szeto; 
  • Jarett Anderson; 
  • Jalal Maghfour; 
  • Maya Matheny; 
  • Quan Nguyen Minh Le; 
  • Michael Kamara; 
  • Robert Dellavalle

ABSTRACT

Background:

N/A

Objective:

N/A

Methods:

N/A

Results:

N/A

Conclusions:

N/A


 Citation

Please cite as:

Sivesind TE, Szeto MD, Anderson J, Maghfour J, Matheny M, Le QNM, Kamara M, Dellavalle R

Pharmaceutical Payments to Authors of Dermatology Guidelines After Publication

JMIR Dermatol 2022;5(2):e37749

DOI: 10.2196/37749

PMID: 37632871

PMCID: 10334891

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.